Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that androgenic alopecia may serve as an early marker for benign prostatic hyperplasia.

This study observed that adherence to finasteride treatment in patients with benign prostatic hyperplasia at a clinic in Tepic Nayarit had not been previously evaluated in Mexico.

In this experimental study on Holtzman rats with induced benign prostatic hyperplasia, the researchers observed that the extract of Physalis peruviana (aguaymanto) had a greater therapeutic effect on prostate weight reduction and prostatic epithelium height compared to finasteride and terazosine.

This animal study found that berberine may alleviate benign prostatic hyperplasia by reducing inflammation and oxidative stress through inhibition of the NF-κB signaling pathway.

This commentary discusses the public health implications of benign prostatic hyperplasia (BPH) and provides no new research results.

This review discusses various treatments for benign prostatic hyperplasia, comparing medications like finasteride and terazosin, as well as surgical and placebo options, without presenting new clinical findings.

This study found that terazosin, finasteride, or their combination were effective in treating symptoms of benign prostatic hyperplasia.

This review discusses finasteride, developed by Merck, as a treatment for benign prostatic hyperplasia and notes its potential effectiveness for male androgenetic alopecia, but reports no new clinical results.

This editorial examines the use of multiple drugs for treating lower urinary tract symptoms due to benign prostatic hyperplasia but offers no new research findings.

This study found that family caregivers reported significantly longer sleep onset latency compared to carefully matched non-caregiving controls, with depressive symptoms predicting poorer sleep quality among caregivers.

In this study, atropine and neosynephrine significantly reduced the incidence of intraoperative floppy iris syndrome during age-related cataract surgery in patients at high risk.

In this case study, concurrent prostatic adenocarcinoma and a rare solitary fibrous tumor were identified on a transurethral resection of the prostate specimen.

This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.

This review discusses recent advancements in understanding the use of 5 alpha-reductase inhibitors for benign prostatic hyperplasia, indicating that dual isoenzyme inhibitors like dutasteride may enhance treatment outcomes, but no new clinical results are presented.

This study found no relationship between androgenic alopecia and parameters such as PSA level, IPSS, and prostate volume in men over 50.

This study found that oral administration of Curcuma longa L. extract in castrated rats with benign prostate hyperplasia reduced pro-inflammatory cytokine expression, suggesting a potential anti-inflammatory effect.

This study found that tamsulosin and finasteride may improve cardiac function and reduce prostatic volume in elderly male patients with chronic heart failure and benign prostatic hyperplasia.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.

This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.

In this study, preoperative use of finasteride was associated with reduced blood loss and vascular endothelial growth factor expression during TURP, suggesting a potential benefit in preventing transurethral resection syndrome.

This article describes a new synthesis method for finasteride that reduces the use of costly and toxic reagents, making it more suitable for large-scale production, but reports no clinical results.

This study found that the combination therapy of Flosin and Prostamol Uno over nine years was well tolerated and equally effective in managing benign prostatic hyperplasia symptoms as the combination of doxazosin and finasteride, with fewer adverse events reported.

This article reviews research on the treatment of benign prostatic hyperplasia and suggests that 5-alpha-reductase inhibitors like finasteride may improve therapeutic outcomes, without providing new clinical results.

In this study, researchers found that androgen receptor gene polymorphism is associated with higher androgenetic alopecia grades and PSA levels in men with benign prostatic hyperplasia, but not with prostate cancer.

This study reported that ginseng had a superior therapeutic effect on benign prostatic hyperplasia in rats, showing nearly normal histological architecture compared to finasteride's incomplete restoration.